Related Experiment Video

Updated: Jun 26, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Advances in oncolytic virus therapy for glioma

Amy Haseley1, Christopher Alvarez-Breckenridge, Abhik Ray Chaudhury

  • 1Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, College of Medicine, The Ohio State University Medical Center, Columbus, OH 43210, USA.

Recent Patents on CNS Drug Discovery
|January 20, 2009
PubMed

Insights

Oncolytic virus therapy shows promise for glioblastoma (GBM) treatment. While safe in trials, further research is needed to confirm significant efficacy and optimize viral strategies against the tumor microenvironment.

Area of Science:

  • Neuro-oncology
  • Virology
  • Biotechnology

Background:

  • Astrocytomas, particularly Grade IV gliomas (glioblastoma), have a poor prognosis.
  • Oncolytic virus therapy represents a novel treatment strategy for glioblastoma multiforme (GBM).
  • Current research focuses on enhancing the efficacy of oncolytic viruses through genetic engineering.

Purpose of the Study:

  • To review the current landscape of oncolytic virus therapy for GBM.
  • To explore innovative strategies for improving oncolytic virus efficacy.
  • To assess the potential of oncolytic viruses in combating the tumor microenvironment.

Main Methods:

  • Review of patents and clinical trial data on oncolytic viruses (e.g., HSV-1, Adenovirus, Reovirus, New Castle Disease Virus).
  • Analysis of viral redesign strategies targeting tumor microenvironment.
  • Evaluation of approaches including cytokine expression, angiostatic genes, and extracellular matrix-digesting enzymes.

Main Results:

  • Clinical trials demonstrate the safety of oncolytic virus therapy for GBM patients.
  • Significant therapeutic efficacy of oncolytic viruses remains to be definitively established.
  • Patented innovations focus on enhancing viral activity against tumor vasculature and extracellular matrix.

Conclusions:

  • Oncolytic virus therapy is a safe and evolving treatment for glioblastoma.
  • Future directions involve engineering viruses to modulate the tumor microenvironment and enhance anti-tumor immunity.
  • Continued development and patenting of novel oncolytic viruses offer a promising outlook for glioma treatment.

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...